BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 28, 2012
View Archived Issues
EE-TP shows promise for the treatment of MNGIE
Read More
New DNA supercoiling inhibitors for bacterial infections presented by Biota
Read More
Kalidex conducts phase I study of novel fluoroquinolone antibiotic
Read More
Teijin Pharma gains rights to investigational bronchial asthma drug
Read More
ASSURE trial of RVX-208 completes enrollment
Read More
Cannabis Science initiates European preclinical program for CS-TATI-1
Read More
Prozymex presents novel dipeptidyl peptidase 1 inhibitors
Read More
Chinese researchers synthesize new androgen receptor antagonists
Read More
Abbott launches Absorb bioresorbable vascular scaffold
Read More
Sanofi discloses several new agents for diabetes
Read More
Reckitt Benckiser to discontinue supply of Suboxone tablets in U.S.
Read More
Array BioPharma and Genentech report novel ERK inhibitors
Read More
Forest Laboratories submits NDA for levomilnacipran
Read More
Pharming completes phase III Ruconest study
Read More
FDA grants priority review status to sNDA for Amitiza
Read More
Bristol-Myers Squibb files application in Japan for Taxol for germ cell tumors
Read More
FDA acknowledges receipt of NDA resubmission for Eliquis
Read More
Pfizer and Acura Pharmaceuticals terminate license agreement
Read More
FDA accepts NDA for FF/VI for COPD
Read More
EMA recommends approval of ingenol mebutate for actinic keratosis
Read More
UCB's phase IIb study of olokizumab meets primary endpoint
Read More
Positive results reported from phase Ib trial of ACH-3102
Read More
BioMarin to start phase III program for PEG-PAL in 2013
Read More
Merck & Co. returns vernakalant rights
Read More
FDA approves Bayer's Stivarga for treatment of metastatic colorectal cancer
Read More